1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Issue 1 (July 2016) Authors: Brunt, A. Murray; Wheatley, Duncan; Yarnold, John; Somaiah, Navita; Kelly, Stephen; Harnett, Adrian; Coles, Charlotte; Goodman, Andrew; Bahl, Amit; Churn, Mark; Zotova, Rada; Sydenham, Mark; Griffin, Clare L; Morden, James P; Bliss, Judith M Journal: Radiotherapy and oncology Issue: Volume 120:Issue 1(2016:Jul.) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. (December 2022) Authors: Bahl, Amit; Wilson, William; Ball, Jessica; Renninson, Emily; Dubey, Sidharth; Bravo, Alicia; Foulstone, Emily; Spensley, Saiqa; Bowen, Rebecca; Mansi, Janine; Waters, Simon; Riddle, Pippa; Wheatley, Duncan; Stephens, Peter; Bezecny, Pavel; Madhusudan, Srinivasan; Verrill, Mark; Braybrooke, Jerem... Journal: Breast Issue: Volume 66(2022) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Issue 10237 (23rd May 2020) Authors: Murray Brunt, Adrian; Haviland, Joanne S; Wheatley, Duncan A; Sydenham, Mark A; Alhasso, Abdulla; Bloomfield, David J; Chan, Charlie; Churn, Mark; Cleator, Susan; Coles, Charlotte E; Goodman, Andrew; Harnett, Adrian; Hopwood, Penelope; Kirby, Anna M; Kirwan, Cliona C; Morris, Carolyn; Nabi, Zohal... Journal: Lancet Issue: Volume 395:Issue 10237(2020) Page Start: 1613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Issue 5 (May 2020) Authors: King, Madeleine T; Link, Emma K; Whelan, Tim J; Olivotto, Ivo A; Kunkler, Ian; Westenberg, Antonia Helen; Gruber, Guenther; Schofield, Penny; Chua, Boon H; Chua, Boon H; Phillips, Claire; Bryant, Guy; Westenberg, Helen; Purohit, Om Pra-Kesh; Ahern, Verity; Graham, Peter; Akra, Mohamed; McArdle, O... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 685 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. (January 2020) Authors: Fernando, Indrajit N.; Bowden, Sarah J.; Herring, Kathryn; Brookes, Cassandra L.; Ahmed, Ikhlaaq; Marshall, Andrea; Grieve, Robert; Churn, Mark; Spooner, David; Latief, Talaat N.; Agrawal, Rajiv K.; Brunt, Adrian M.; Stevens, Andrea; Goodman, Andrew; Canney, Peter; Bishop, Jill; Ritchie, Diana; D... Journal: Radiotherapy and oncology Issue: Volume 142(2020) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗